Skip to content

THE GENOTYPE AND PHENOTYPE CORRELATIONS IN AUTISM SPECTRUM DISORDERS

THE GENOTYPE AND PHENOTYPE CORRELATIONS IN AUTISM SPECTRUM DISORDERS - GPASD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON32673
Enrollment
1600
Registered
2008-11-12
Start date
2009-01-07
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism autistic disorder

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
2 Years to 99 Years

Inclusion criteria

Inclusion criteria: General Inclusion criteria 1) Aged at least 4 years ;Inclusion criteria for subjects with ASD 2) DSM-IV (APA, 1994) diagnosis in the autism spectrum, according to ADI-R interview and ADOS;Inclusion criteria for controls 2) No psychiatric disorders or behavioural problems as reflected by scores on the CBCL in the normal range. 3) no significant social problems as reflected by a score on the SRS in the normal range 4) No ASD in their first degree relatives. 5) IQ > 70

Exclusion criteria

Exclusion criteria: Exclusion criteria 1) Major illness of the cardiovascular, the endocrine, the pulmonal or the gastrointestinal system 2) History of or present neurological disorder 3) For individuals over 12 years of age: legal incompetence, defined as the obvious inability to comprehend the information that is presented by the investigator and is outlined in the Information letter and on which the decision to participate in the study is to be based

Design outcomes

Primary

MeasureTime frame
Study parameters/outcome of the study: The parameters of the study are the genotype of common variants for ASD, possible CNVs and gene-expression patterns. The outcome measures are specific subtypes of ASD revealed by clustering of neuropsychological and behavioural symptoms as well as the severity of symptoms as measured with specific clinical instruments (questionnaires, diagnostic interview and observation-instrument and neuropsychological tasks (see chapter clinical phenotyping).

Secondary

MeasureTime frame
None

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)